This story was sponsored and fact checked by Marantz

Marantz is redefining what reference level home theater looks and sounds like for today’s listener. The focus is no longer on excess hardware or visual dominance, but on delivering uncompromising performance, meticulous tuning, and premium build quality within a refined, contemporary industrial design that complements modern living spaces. It is theater-grade sound, executed with intention and restraint.

That philosophy comes into full view with the introduction of the AV30 and AMP30, completing Marantz’s new A/V separate series alongside the AV10 and AMP10 and the AV20 and AMP20. The result is a deliberately tiered lineup of preamp/processors and multi-channel amplifiers offering mix-and-match configurations, including support for immersive layouts up to 9.4.6 Dolby Atmos.

Whether building a reference system from the ground up or integrating selectively with the Cinema Series AVRs to add power where it matters most, Marantz has designed an ecosystem that scales performance with consistent visual elegance.

Execution matters at this level, and Marantz’s latest A/V separates reflect that standard. All components are engineered and manufactured at the Marantz Shirakawa Audio Works facility in Japan, and each product is certified by a Marantz Sound Master, currently Yoshinori Ogata, to ensure tuning accuracy, consistency, and performance integrity.

The result is a modern reference platform that prioritizes sound quality, visual refinement, and long term relevance, delivering premium home theater without the traditional equipment rack mentality and signaling clearly where Marantz believes high-end A/V performance belongs today.

From Foundational Engineering to Modern Reference Home Theater

The current Marantz A/V separates continue the ethos, engineering discipline, and design principles established by founder Saul Marantz beginning in 1953. Most notably, the Marantz Model 9 from 1960 introduced the porthole and architectural symmetry that remain defining elements of the 2026 lineup. From the outset, Marantz established a clear technical philosophy centered on precise power control, stability under load, and system designs that balance performance with usability.

Inspired by the proportion and resonance of musical instruments, Marantz components use symmetry not as a stylistic gesture but as a visual expression of control and order, reinforcing the central role of sound rather than competing with it. The iconic porthole carries that same philosophy forward. Originally a functional window for an analog VU meter, it has evolved into a modern aperture into the heart of the component, maintaining a sense of connection between listener and system whether the technology inside is analog or digital.

The warmth long associated with Marantz sound is equally present in its physical form. Materials, finishes, and color choices are selected to feel inviting rather than clinical, while controls are designed to respond with precision and confidence in hand. Anchoring it all is the Marantz mark, placed deliberately at the pinnacle of each product as a quiet statement of lineage and intent.

As formats evolved and system complexity increased, Marantz expanded its engineering and tuning operations, reinforcing a culture of precision and consistency. Rather than treating home theater as a departure from high-fidelity design, Marantz applied its amplification expertise directly to multichannel systems, focusing on clarity, spatial coherence, and controlled dynamics across increasingly demanding channel counts.

A key technical milestone followed with the development of Hyper Dynamic Amplifier Module technology. Created as a discrete alternative to conventional integrated circuits, HDAM established Marantz’s approach to faster signal response, wider bandwidth, and more precise dynamic control—an architecture that continues to define the brand’s amplification.

That lineage is carried forward in Marantz’s latest A/V separates, which translates decades of amplification and tuning expertise into reference-level home theater as it is experienced today.

A Tiered Reference System Designed for Modern Home Theater

Marantz’s current A/V separates are designed as a deliberately tiered system rather than a single statement product. The lineup comprises three preamp processors, the AV10, AV20, and AV30, and three multichannel power amplifiers, the AMP10, AMP20, and AMP30, allowing system builders to scale performance while maintaining a consistent design and tuning philosophy.

The newest additions, the AV30 and AMP30, serve as the most accessible entry point in the lineup, complemented by the AV20 and AMP20 and the flagship AV10 and AMP10. Together, they form three clearly defined performance tiers that allow systems to scale without sacrificing a unified design language or tuning philosophy.

Signal integrity, tonal balance, and amplification control are consistent across the Marantz separates range. The differences come down to channel capacity. The AV30 supports up to 7.4.4 Dolby Atmos processing, the AV20 adds 2 additional height or surround channels, and the flagship AV10 expands that by another 2 channels. The amplifier lineup follows the same logic: the AMP30 provides 6 channels, the AMP20 offers 12, and the AMP10 tops the range with 16. All amplifier channels are rated at 200 watts into 8 ohms and support bi-amping or bridging, which doubles output to 400 watts per channel.

With support for immersive configurations from 11 to 15 channels, Marantz A V separates are well suited to high-performance living spaces and dedicated theaters where integration, efficiency, and visual restraint matter as much as output. Their focus is consistency, maintaining clarity, stability, and coherence as channel counts and speaker demands increase. All three AMP models also provide a flexible upgrade path for Marantz Cinema Series AVR owners who need additional power or channel expansion.

The result is a separates platform defined by flexibility rather than hierarchy. Whether beginning with the AV30 and AMP30 or building toward a flagship configuration, each tier reflects the same approach to amplification, tuning, and industrial design.

AV30 and AMP30: A Modern Entry Point to Marantz Reference Home Theater

Marantz reinforces its tiered separates strategy with the AV30 and AMP30 by addressing a buyer who wants a high-performance home theater that is equally capable with film, music, and modern displays. Positioned as the most accessible entry point in the Marantz separates lineup, the pairing is designed to deliver the core elements that matter at this level: format flexibility, system integration, and the ability to adapt as the system and room evolve.

The AV30 serves as the system’s control center, supporting the surround formats that define today’s premium home theater, including Dolby Atmos, DTS X, Auro 3D, and IMAX Enhanced. Four independent subwoofer outputs allow precise low-frequency integration and compatibility with advanced room optimization such as Dirac Live ART. On the video side, support for HDR10, HDR10+, Dolby Vision, HLG, and Dynamic HDR pass-through ensures full compatibility with modern displays and high-quality sources.

Beyond home theater, the AV30 is designed to integrate easily into everyday listening. It supports a wide range of streaming services, including Amazon Music, TIDAL, Deezer, Napster, and SoundCloud, Qobuz Connect, and is Roon Ready for library-based playback. HEOS enables multiroom integration, while Bluetooth, Apple AirPlay 2, and Wi-Fi provide straightforward access across devices and use cases.

Paired with the AV30, the AMP 30 delivers controlled, scalable amplification for modern multichannel systems. Its six-channel Class D design provides up to 200 watts per channel, reinforced by Marantz’s HDAM-SA2 circuitry for stability and tonal consistency. Systems can grow by adding additional AMP30 units or pairing with higher-channel-count amplifiers such as the AMP20, while support for bi-amp and bridge-tied load configurations and both XLR and RCA inputs keeps integration straightforward.

Taken together, the AV30 and AMP30 form a cohesive foundation for buyers considering an $8,000 separates investment. As a system, they deliver modern surround processing, refined low-frequency control, scalable amplification, and seamless integration with both home theater and whole-home audio environments.

More importantly, they reflect Marantz’s long-standing priorities; clarity, control, and thoughtful system design applied to the realities of contemporary home theater, where performance must coexist with flexibility and long-term relevance.

Tip: In the coming weeks our Editor-at-Large, Chris Boylan will be releasing his hands-on review of the AV30, AMP30 and AMP20.

Price & Availability

Home Theater Preamplifier/Processors:

Multi-channel Power Amplifiers:

For more information, visit marantz.com

Related Reading:

AI assistants like Grok and Microsoft Copilot with web browsing and URL-fetching capabilities can be abused to intermediate command-and-control (C2) activity.

Researchers at cybersecurity company Check Point discovered that threat actors can use AI services to relay communication between the C2 server and the target machine.

Attackers can exploit this mechanism to deliver commands and retrieve stolen data from victim systems.

The researchers created a proof-of-concept to show how it all works and disclosed their findings to Microsoft and xAI.

AI as a stealthy relay

Instead of malware connecting directly to a C2 server hosted on the attacker’s infrastructure, Check Point’s idea was to have it communicate with an AI web interface, instructing the agent to fetch an attacker-controlled URL and receive the response in the AI’s output.

In Check Point’s scenario, the malware interacts with the AI service using the WebView2 component in Windows 11. The researchers say that even if the component is missing on the target system, the threat actor can deliver it embedded in the malware.

WebView2 is used by developers to show web content in the interface of native desktop applications, thus eliminating the need of a full-featured browser.

The researchers created “a C++ program that opens a WebView pointing to either Grok or Copilot.” This way, the attacker can submit to the assistant instructions that can include commands to be executed or extract information from the compromised machine.

The webpage responds with embedded instructions that the attacker can change at will, which the AI extracts or summarizes in response to the malware’s query.

The malware parses the AI assistant’s response in the chat and extracts the instructions.

This creates a bidirectional communication channel via the AI service, which is trusted by internet security tools and can thus help carry out data exchanges without being flagged or blocked.

Check Point’s PoC, tested on Grok and Microsoft Copilot, does not require an account or API keys for the AI services, making traceability and primary infrastructure blocks less of a problem.

“The usual downside for attackers [abusing legitimate services for C2] is how easily these channels can be shut down: block the account, revoke the API key, suspend the tenant,” explains Check Point.

“Directly interacting with an AI agent through a web page changes this. There is no API key to revoke, and if anonymous usage is allowed, there may not even be an account to block.”

The researchers explain that safeguards exist to block obviously malicious exchanges on the said AI platforms, but these safety checks can be easily bypassed by encrypting the data into high-entropy blobs.

CheckPoint argues that AI as a C2 proxy is just one of multiple options for abusing AI services, which could include operational reasoning such as assessing if the target system is worth exploiting and how to proceed without raising alarms.

BleepingComputer has contacted Microsoft to ask whether Copilot is still exploitable in the way demonstrated by Check Point and the safeguards that could prevent such attacks. A reply was not immediately available, but we will update the article when we receive one.

Modern IT infrastructure moves faster than manual workflows can handle.

In this new Tines guide, learn how your team can reduce hidden manual delays, improve reliability through automated response, and build and scale intelligent workflows on top of tools you already use.

Get the guide

Like many Silicon Valley companies today, Scout AI is training large AI models and agents to automate chores. The big difference is that instead of writing code, answering emails, or buying stuff online, Scout AI’s agents are designed to seek and destroy things in the physical world with exploding drones.

In a recent demonstration, held at an undisclosed military base in central California, Scout AI’s technology was put in charge of a self-driving off-road vehicle and a pair of lethal drones. The agents used these systems to find a truck hiding in the area, and then blew it to bits using an explosive charge.

“We need to bring next-generation AI to the military,” Colby Adcock, Scout AI’s CEO, told me in a recent interview. (Adcock’s brother, Brett Adcock, is the CEO of Figure AI, a startup working on humanoid robots). “We take a hyperscaler foundation model and we train it to go from being a generalized chatbot or agentic assistant to being a warfighter.”

Adcock’s company is part of a new generation of startups racing to adapt technology from big AI labs for the battlefield. Many policymakers believe that harnessing AI will be the key to future military dominance. The combat potential of AI is one reason why the US government has sought to limit the sale of advanced AI chips and chipmaking equipment to China, although the Trump administration recently chose to loosen those controls.

“It’s good for defense tech startups to push the envelope with AI integration,” says Michael Horowitz, a professor at the University of Pennsylvania who previously served in the Pentagon as deputy assistant secretary of defense for force development and emerging capabilities. “That’s exactly what they should be doing if the US is going to lead in military adoption of AI.”

Horowitz also notes, though, that harnessing the latest AI advances can prove particularly difficult in practice.

Large language models are inherently unpredictable and AI agents—like the ones that control the popular AI assistant OpenClaw—can misbehave when given even relatively benign tasks like ordering goods online. Horowitz says it may be especially hard to demonstrate that such systems are robust from a cybersecurity standpoint—something that would be required for widespread military use.

Scout AI’s recent demo involved several steps where AI had free rein over combat systems.

At the outset of the mission the following command was fed into a Scout AI system known as Fury Orchestrator:

Fury Orchestrator, send 1 ground vehicle to checkpoint ALPHA. Execute a 2 drone kinetic strike mission. Destroy the blue truck 500m East of the airfield and send confirmation.

A relatively large AI model with over a 100 billion parameters, which can run either on a secure cloud platform or an air-gapped computer on-site, interprets the initial command. Scout AI uses an undisclosed open source model with its restrictions removed. This model then acts as an agent, issuing commands to smaller, 10-billion-parameter models running on the ground vehicles and the drones involved in the exercise. The smaller models also act as agents themselves, issuing their own commands to lower-level AI systems that control the vehicles’ movements.

Seconds after receiving marching orders, the ground vehicle zipped off along a dirt road that winds between brush and trees. A few minutes later, the vehicle came to a stop and dispatched the pair of drones, which flew into the area where it had been instructed that the target was waiting. After spotting the truck, an AI agent running on one of the drones issued an order to fly toward it and detonate an explosive charge just before impact.

Today, district leaders are being asked to make irreversible budget decisions with fewer dollars and less margin for error than ever before. Yet many districts are making those decisions with limited evidence of what actually works in their classrooms — not because leaders lack interest in data, but because few systems are designed to support real-time learning at the district level.

For school and district leaders, quality data is key. Without strong research, data and connections, district leaders can find themselves working in silos, testing similar ideas in parallel without a shared way to learn what works, what does not and why.

“Right now, education research and development (R&D) isn’t about experimentation; it’s about making smarter bets with limited resources,” shared Jillian Doggett, director of the League of Innovative Schools at Digital Promise.

“R&D has to be embedded in a district’s DNA so that we are not making decisions based on assumptions of what we think works, or on what worked five or 10 years ago,” said Doggett.

That shift requires moving past a traditional approach in which programs are adopted districtwide before leaders have meaningful local evidence of fit or impact.

Dr. Robert Hill, superintendent and chief executive officer of the Springfield City School District in Ohio, argues that meeting students’ needs requires stepping beyond familiar models. To him, research and development is a way to test new approaches, learn quickly and build evidence before scaling.

“Through R&D, we can think outside the box, build evidence through continuous improvement and then advance policy, with funding attached, that actually supports kids,” Hill said.

How Districts Are Prioritizing Research and Development

Hill’s belief in the connection between R&D and student outcomes led him to join a national advisory group of district leaders focused on making education research more responsive to real-time needs.

Prioritizing research and development has already led to measurable progress for Hill’s district. As part of a chronic absenteeism cohort, Hill and his team worked with peer districts to test strategies, analyze real-time attendance data and refine approaches based on what was actually driving shifts in student engagement. Rather than relying on a single program or past assumptions, the district used an inclusive innovation model to identify which interventions were effective.

“Research and development has helped us better engage our students,” Hill shared. “By aligning student interests to career pathways and connecting that with labor market data, we are actually seeing forward progress on our academic outcomes.”

For Dr. Audra Pittman, superintendent of Calistoga Joint Unified School District in rural California, engaging in education research and development helps ensure her district operates through an equity lens. Her approach to innovation is grounded in the belief that if current practices are not working for all students, districts have an obligation to keep trying new approaches.

Through a structured research partnership, Pittman’s district is examining how families and staff can partner more effectively through a cohesive, district-wide engagement and support approach centered on a co-design framework. This work asks not only whether something works, but also for whom, under what conditions and why.

The partnership allows Pittman’s team to pilot ideas thoughtfully, balancing innovation with the realities of limited time and capacity.

Why Collaboration Is Essential to Scaling What Works

Alongside education research and development, Pittman attributes strong connections with peers across the country to turning local insights into broader change.

“There’s a lot of good work that’s occurring across our nation,” said Pittman. Through participation in a national learning network, leaders like Hill and Pittman test, share and refine practices through issue-focused cohorts, innovative partnerships and regular in-person touchpoints.

As a busy superintendent, Pittman knows how difficult it can be to identify new methods she can trust. Engaging with peers who are testing emerging approaches and sharing evidence of impact has supported more efficient, informed decision-making.

Doggett has seen districts benefit from this hands-on approach to research and development, including access to research partnerships, shared tools and opportunities to learn across systems.

“That connective tissue allows district-led R&D to move quickly, learn in real time and extend beyond individual districts.”

From Policy to Action

The collaborative efforts of district leaders matter not only for research and development but also for policy.

“It’s necessary to have conversations with [policymakers] to express the challenges we are facing, the flexibility that’s necessary to advance an R&D model, and the funding that’s associated with that,” Hill shared.

Traditional funding structures often require districts to commit to specific programs upfront, leaving little room for the iterative testing that defines effective research and development. As a result, districts are often forced to choose certainty over learning — even when that certainty is more assumed than proven.

Late last year, Hill, Pittman and other district leaders convened in Washington, D.C., to make the case for a reimagined approach to funding that better supports effective education R&D.

During those meetings, leaders shared how collaborative research and development efforts have supported improvements in teaching and learning and discussed ways to scale effective practices. They called for sustained investment, greater flexibility to reduce barriers to innovation and more transparent sharing of results to accelerate learning and advance equity nationwide.

“When you’re surrounded by districts from across the nation, you are reminded that education … is truly a bipartisan issue,” Pittman reflected. “We are somewhat divided now, and this is an opportunity to bring us back together.”

Are you interested in tapping into a national learning community through the League of Innovative Schools? Sign up to be the first to hear when the League’s next application cycle is live.

Flare researchers monitoring underground Telegram channels and cybercrime forums have observed threat actors rapidly sharing proof-of-concept exploits, offensive tools, and stolen administrator credentials related to recently disclosed SmarterMail vulnerabilities, providing insight into how quickly attackers weaponize new security flaws.

The activity occurred within days of the vulnerabilities being disclosed, with threat actors sharing and selling exploit code and compromised access tied to CVE-2026-24423 and CVE-2026-23760, critical flaws that enable remote code execution and authentication bypass on exposed email servers.

These vulnerabilities have since been confirmed in real-world attacks, including ransomware campaigns, highlighting how attackers increasingly target email infrastructure as an initial access point into corporate networks, allowing them to move laterally and establish persistent footholds.

CVE-2026-24423 and CVE-2026-23760: Critical RCE and Auth Bypass Flaws

Multiple recently disclosed SmarterMail vulnerabilities created a perfect storm that made the platform highly attractive to attackers. Among them, CVE-2026-24423 stands out as a critical unauthenticated remote code execution flaw affecting versions prior to Build 9511.

With a CVSS score of 9.3 and no user interaction required, the flaw is particularly suited for automation, large-scale scanning, and mass exploitation campaigns.

In parallel, additional vulnerabilities CVE-2026-23760 (CVSS 9.3) include authentication bypass and password reset logic flaws. It allows attackers to reset administrator credentials or gain privileged access to the platform. Research also shows that attackers were quickly reverse-engineering patches to identify and weaponize these weaknesses within days of release.

When combined, these issues enabled full server takeover scenarios, where attackers could move from application-level access to operating system control and potentially domain-level compromise in connected environments.

From an attacker’s perspective, this combination is ideal: SmarterMail is a network-exposed service, often holds a high trust position inside enterprise environments, and in many cases is monitored less aggressively than endpoint systems protected by EDR.

Once proof-of-concept exploit code becomes available, exploitation can be rapidly operationalized – meaning the timeline from vulnerability disclosure to ransomware deployment can shrink to days.

SmarterTools Breached by Own Product Flaw, Ransomware Groups Follow

Recent incidents demonstrate exactly how this pipeline plays out.

According to a SmarterTools report, SmarterTools was breached in January 2026 after attackers exploited an unpatched SmarterMail server running on an internal VM that was exposed inside their network.

The compromised environment included office and lab networks and a data-center segment connected through Active Directory, where attackers moved laterally and impacted around a dozen Windows servers.

The company shut down the affected infrastructure, restored systems from backup, rotated credentials, and removed some Windows/AD dependencies. Having said that, it was reported that core customer services and data were unaffected. Attackers gained an internal network foothold and attempted typical ransomware-style post-exploitation actions; it wasn’t successful, thanks to network segmentation.

In another investigation published by Bleeping Computer, ransomware operators gained initial access through SmarterMail vulnerabilities and waited before triggering encryption payloads, a classic affiliate behavior pattern.

This pattern is important:

1. Initial access via email server vulnerability
2. Credential harvesting or token extraction
3. Lateral movement via Active Directory
4. Persistence via scheduled tasks or DFIR tool abuse
5. Ransomware deployment after staging period

Some campaigns have been linked to the Warlock ransomware group, with overlaps observed with nation-state-aligned activity clusters.

Email Servers: Identity Infrastructure Attackers Target First

Email servers sit at a unique intersection of trust and visibility.

They often provide:

• Domain authentication tokens
• Password reset capabilities
• External communication channels
• Access to internal contact graphs
• Integration with identity and directory services

Attackers understand that email ecosystems rely on multi-component authentication chains where a single weak link can break overall trust. Compromise the email infrastructure and you effectively compromise identity.

1,200+ Vulnerable Servers Identified on Shodan

We found ~34,000 servers on Shodan with indications of running SmarterMail. Out of the 34,000, there were 17,754 unique servers.

A further inspection of these servers shows that 1,185 are vulnerable to authentication bypass or RCE flaws. Other publications talk about ~6,000 vulnerable servers.

A geo-location analysis of these 1,185 servers shows US dominance:

A further analysis of the ISPs and Organizations shows a very diverse distribution of open SmarterMail servers, many self-hosted admin panels, shared hosting, VPS providers, and general-purpose cloud networks, typical of deployment by individuals rather than organizations.

This may indicate that after the strong security hype over the past weeks, organizations were quick to react and block this attack surface.

Underground Forums Share Exploits Within Days of Disclosure

The underground ecosystems are fast to react to such publications. The CVEs were published around the beginning of January, and on the same day, there were mentions and references to these vulnerabilities. To date, we’ve seen dozens of publications and references to these vulnerabilities.

This is normal underground behavior when it comes to critical vulnerabilities.

We have also seen some more malicious references. A few days after the first publication, there were references to Proof of Concept or exploit of the vulnerabilities. For instance, an Arabic-speaking Telegram channel shows PoC.

You can also see how the threat actor is showing proof of concept:

And another threat actor is showing a proof of concept to this vulnerability:

In a Spanish-speaking Telegram group, we saw references to an Offensive Security Tool:

On another Telegram group, we saw a data dump of admin credentials highlighted as it comes from a compromised SmarterMail server:

When accessing one of the links, you can indeed see a long list of admin credentials and the domains (or login) to which they belong.

CISA Confirms Active Exploitation in Ransomware Campaigns

These vulnerabilities were published in the beginning of 2026, CISA added CVE-2026-24423 to the Known Exploited Vulnerabilities catalog in the beginning of February 2026, after confirming active ransomware exploitation.

This confirms that attackers are quick to exploit newly discovered critical RCE- related vulnerabilities:

• Vulnerability disclosure
• PoC written and released
• Mass scanning operation
• Weaponization: Data exfiltration, Ransomware etc.

Timeline shrinking from months/weeks to days.

How to Protect Email Infrastructure From Ransomware Access

Many organizations still treat email servers as “ONLY application infrastructure”. Well, they are not!

They are identity infrastructures that enable many follow-up attack vectors, as well as containing secrets and business logic. Defensive priorities should include:

• Patch Urgency: Critical email server vulnerabilities should be treated like domain controller vulnerabilities.
• Identity Telemetry: Organizations should monitor these environments for:
  • Admin password resets
  • API calls to external hosts
  • Unexpected outbound HTTP from mail servers

• Network Segmentation: Email infrastructure should never have unrestricted access to internal networks.
• Threat Hunting Practice:
  • API abuse patterns
  • Scheduled task persistence
  • Unexpected tooling like DFIR frameworks or remote admin tools

Email Servers Are Identity Infrastructure—Secure Them Accordingly

The SmarterMail cases show once again how modern cybercrime operations are quick to add newly discovered initial access to their ongoing operation.

It also re-emphasizes the critical role email servers take in the modern organization:

• Identity brokers
• Trust anchors
• Business logic
• Invaluable reconnaissance data for follow-up cybercrime

Organizations that continue treating them as just “messaging systems” will remain vulnerable to this new generation of intrusion pipelines.

Learn more by signing up for our free trial.

Sponsored and written by Flare.

The Pixel 10A is now here, bringing a lower-cost option to Google’s Pixel 10 lineup. Starting at just $500, the Pixel 10A is more affordable than the $800 Pixel 10, and it’s significantly cheaper than the $1,000 Pixel 10 Pro and the $1,200 10 Pro XL.

Watch this: Google’s $499 Pixel 10A Launches with AirDrop Support and Faster Charging

03:35

Yet, despite a number of tradeoffs to hit its lower price, the 10A is not too shabby. These trade-offs include using the Tensor G4 processor instead of the newer Tensor G5, and the fact that PixelSnap magnetic accessories won’t attach directly to the phone. Still, if you can live without those upgrades, you’re getting a full-featured phone at a relatively low price.

Here’s how the Pixel 10A compares with the rest of Google’s Pixel 10 lineup. 

Display

When it comes to display quality, the Pixel 10A compares very well to the rest of the Pixel 10 lineup. It has almost the same exact specs as the Pixel 10, with a 6.3-inch pOLED (the Pixel 10 has a 6.3-inch OLED instead), 2,424 x 1,080 pixel resolution and a 60 to 120 Hertz variable refresh rate.

Of course, the 10 Pro and 10 Pro XL are more premium. The 10 Pro has a 6.3-inch LTPO OLED, 2,856 x 1,280 pixel resolution and a 1 to 120 Hertz variable refresh rate, while the 10 Pro XL has a 6.8-inch LTPO OLED, 2,992 x 1,344 pixel resolution and the same refresh rate.

Advertisement

Cameras

While most of the Pixel 10 series has at least three rear cameras, the 10A has just two. The 10A has a 48-megapixel wide and a 13-megapixel ultrawide camera, while the 10 has a 48-megapixel wide, a 13-megapixel ultrawide and a 10.8-megapixel 5x telephoto. Both the 10 Pro and the 10 Pro XL have a 50-megapixel wide, a 48-megapixel ultrawide and a 48-megapixel 5x telephoto. Both the 10A and the 10 have 4K video capture, while the 10 Pro and 10 Pro XL have 8K video capture. 

The 10A does have a fairly decent front-facing camera with a 13-megapixel selfie cam, while the 10 only has a 10.5-megapixel front-facing camera. The 10 Pro and 10 Pro XL have 42-megapixel front-facing cameras. 

Advertisement

Battery and Performance

Surprisingly, the Pixel 10A actually has a bigger battery than some of its more expensive brethren. The 10A has a 5,100-mAh battery, which is more than the Pixel 10’s 4,970-mAh battery as well as the 10 Pro’s 4,870-mAh battery. The 10 Pro XL, however, does have a slightly larger 5,200-mAh battery, befitting its more premium features. 

The Pixel 10A has 30W wired fast charging when using a 45W charging adapter, which matches  the 30W wired fast charging on the Pixel 10 and the 10 Pro. As for wireless charging, the 10A supports up to 10W (Qi-certified), which isn’t quite as good as the Qi2 15W speed on the Pixel 10 and the 10 Pro, and the Qi2.2 25W speed on the Pixel 10 Pro XL.

Processor-wise, the Pixel 10A has the same Google Tensor G4 as its predecessor, while the pricier 10, 10 Pro and 10 Pro XL all have the upgraded Google Tensor G5. The Pixel 10A also only has 8GB of RAM, which is considered the bare minimum these days. By contrast, the 10 has 12GB of RAM while the 10 Pro and 10 Pro XL both have 16GB of RAM. 

Check out the chart to see more ways the Pixel 10A compares to the rest of the Pixel 10 line.

One day soon, a doctor might prescribe a pill that doesn’t just deliver medicine but also reports back on what it finds inside you—and then takes actions based on its findings.

Instead of scheduling an endoscopy or CT scan, you’d swallow an electronic capsule smaller than a multivitamin. As it travels through your digestive system, it could check tissue health, look for cancerous changes, and send data to your doctor. It could even release drugs exactly where they’re needed or snip a tiny biopsy sample before passing harmlessly out of your body.

This dream of a do-it-all pill is driving a surge of research into ingestible electronics: smart capsules designed to monitor and even treat disease from inside the gastrointestinal (GI) tract. The stakes are high. GI diseases affect tens of millions of people worldwide, including such ailments as inflammatory bowel disease, celiac disease, and small intestinal bacterial overgrowth. Diagnosis often involves a frustrating maze of blood tests, imaging, and invasive endoscopy. Treatments, meanwhile, can bring serious side effects because drugs affect the whole body, not just the troubled gut.

If capsules could handle much of that work—streamlining diagnosis, delivering targeted therapies, and sparing patients repeated invasive procedures—they could transform care. Over the past 20 years, researchers have built a growing tool kit of ingestible devices, some already in clinical use. These capsule-shaped devices typically contain sensors, circuitry, a power source, and sometimes a communication module, all enclosed in a biocompatible shell. But the next leap forward is still in development: autonomous capsules that can both sense and act, releasing a drug or taking a tissue sample.

That’s the challenge that our lab—the MEMS Sensors and Actuators Laboratory (MSAL) at the University of Maryland, College Park—is tackling. Drawing on decades of advances in microelectromechanical systems (MEMS), we’re building swallowable devices that integrate sensors, actuators, and wireless links in packages that are small and safe enough for patients. The hurdles are considerable: power, miniaturization, biocompatibility, and reliability, to name a few. But the potential payoff will be a new era of personalized and minimally invasive medicine, delivered by something as simple as a pill you can swallow at home.

The Origin of Ingestible Devices

The idea of a smart capsule has been around since the late 1950s, when researchers first experimented with swallowable devices to record temperature, gastric pH, or pressure inside the digestive tract. At the time, it seemed closer to science fiction than clinical reality, bolstered by pop-culture visions like the 1966 film Fantastic Voyage, where miniaturized doctors travel inside the human body to treat a blood clot.

One of the authors (Ghodssi) holds a miniaturized drug-delivery capsule that’s designed to release medication at specific sites in the gastrointestinal tract.Maximilian Franz/Engineering at Maryland Magazine

For decades, though, the mainstay of GI diagnostics was endoscopy: a camera on a flexible tube, threaded down the throat or up through the colon. These procedures are quite invasive and require patients to be sedated, which increases both the risk of complications and procedural costs. What’s more, it’s difficult for endoscopes to safely traverse the circuitous pathway of the small intestine. The situation changed in the early 2000s, when video-capsule endoscopy arrived. The best-known product, PillCam, looks like a large vitamin but contains a camera, LEDs, and a transmitter. As it passes through the gut, it beams images and videos to a wearable device.

Today, capsule endoscopy is a routine tool in gastroenterology; ingestible devices can measure acidity, temperature, or gas concentrations. And researchers are pushing further, with experimental prototypes that deliver drugs or analyze the microbiome. For example, teams from Tufts University, in Massachusetts, and Purdue University, in Indiana, are working on devices with dissolvable coatings and mechanisms to collect samples of liquid for studies of the intestinal microbiome.

Still, all those devices are passive. They activate on a timer or by exposure to the neutral pH of the intestines, but they don’t adapt to conditions in real time. The next step requires capsules that can sense biomarkers, make decisions, and trigger specific actions—moving from clever hardware to truly autonomous “smart pills.” That’s where our work comes in.

Building on MEMS technology

Since 2017, MSAL has been pushing ingestible devices forward with the goal of making an immediate impact in health care. The group built on the MEMS community’s legacy in microfabrication, sensors, and system integration, while taking advantage of new tools like 3D printing and materials like biocompatible polymers. Those advances have made it possible to prototype faster and shrink devices smaller, sparking a wave of innovation in wearables, implants, and now ingestibles. Today, MSAL is collaborating with engineers, physicians, and data scientists to move these capsules from lab benches to pharmaceutical trials.

As a first step, back in 2017, we set out to design sensor-carrying capsules that could reliably reach the small intestine and indicate when they reached it. Another challenge was that sensors that work well on the benchtop can falter inside the gut, where shifting pH, moisture, digestive enzymes, and low-oxygen conditions can degrade typical sensing components.

Our earliest prototype adapted MEMS sensing technology to detect abnormal enzyme levels in the duodenum that are linked to pancreatic function. The sensor and its associated electronics were enclosed in a biocompatible, 3D-printed shell coated with polymers that dissolved only at certain pH levels. This strategy could one day be used to detect biomarkers in secretions from the pancreas to detect early-stage cancer.

A high-speed video shows how a capsule deploys microneedles to deliver drugs into intestinal tissue.University of Maryland/Elsevier

That first effort with a passive device taught us the fundamentals of capsule design and opened the door to new applications. Since then, we’ve developed sensors that can track biomarkers such as the gas hydrogen sulfide, neurotransmitters such as serotonin and dopamine, and bioimpedance—a measure of how easily ions pass through intestinal tissue—to shed light on the gut microbiome, inflammation, and disease progression. In parallel, we’ve worked on more-active devices: capsule-based tools for controlled drug release and tissue biopsy, using low-power actuators to trigger precise mechanical movements inside the gut.

Like all new medical devices and treatments, ingestible electronics face many hurdles before they reach patients—from earning physician trust and insurance approval to demonstrating clear benefits, safety, and reliability. Packaging is a particular focus, as the capsules must be easy to swallow yet durable enough to survive stomach acid. The field is steadily proving safety and reliability, progressing from proof of concept in tissue, through the different stages of animal studies, and eventually to human trials. Every stage provides evidence that reassures doctors and patients—for example, showing that ingesting a properly packaged tiny battery is safe, and that a capsule’s wireless signals, far weaker than those of a cellphone, pose no health risk as they pass through the gut.

Engineering a Pill-Size Diagnostic Lab

The gastrointestinal tract is packed with clues about health and disease, but much of it remains out of reach of standard diagnostic tools. Ingestible capsules offer a way in, providing direct access to the small intestine and colon. Yet in many cases, the concentrations of chemical biomarkers can be too low to detect reliably in early stages of a disease, which makes the engineering challenge formidable. What’s more, the gut’s corrosive, enzyme-rich environment can foul sensors in multiple ways, interfering with measurements and adding noise to the data.

Microneedle designs for drug-delivery capsules have evolved over the years. An early prototype [top] used microneedle anchors to hold a capsule in place. Later designs adopted molded microneedle arrays [center] for more uniform fabrication. The most recent version [bottom] integrates hollow microinjector needles, allowing more precise and controllable drug delivery.From top: University of Maryland/Wiley;University of Maryland/Elsevier;University of Maryland/ACS

Take, for example, inflammatory bowel disease, for which there is no standard clinical test. Rather than searching for a scarce biomarker molecule, our team focused on a physical change: the permeability of the gut lining, which is a key factor in the disease. We designed capsules that measure the intestinal tissue’s bioimpedance by sending tiny currents across electrodes and recording how the tissue resists or conducts those currents at different frequencies (a technique called impedance spectroscopy). To make the electrodes suitable for in vivo use, we coated them with a thin, conductive, biocompatible polymer that reduces electrical noise and keeps stable contact with the gut wall. The capsule finishes its job by transmitting its data wirelessly to our computers.

In our lab tests, the capsule performed impressively, delivering clean impedance readouts from excised pig tissue even when the sample was in motion. In our animal studies, it detected shifts in permeability triggered by calcium chelators, compounds that pry open the tight junctions between intestinal cells. These results suggest that ingestible bioimpedance capsules could one day give clinicians a direct, minimally invasive window into gut-barrier function and inflammation. We believe that ingestible diagnostics can serve as powerful tools—catching disease earlier, confirming whether treatments are working, and establishing a baseline for gut health.

Drug Delivery at the Right Place, Right Time

Targeted drug delivery is one of the most compelling applications for ingestible capsules. Many drugs for GI conditions—such as biologics for inflammatory bowel disease—can cause serious side effects that limit both dosage and duration of treatment. A promising alternative is delivering a drug directly to the diseased tissue. This localized approach boosts the drug’s concentration at the target site while reducing its spread throughout the body, which improves effectiveness and minimizes side effects. The challenge is engineering a device that can both recognize diseased tissue and deliver medication quickly and precisely.

With other labs making great progress on the sensing side, we’ve devoted our energy to designing devices that can deliver the medicine. We’ve developed miniature actuators—tiny moving parts—that meet strict criteria for use inside the body: low power, small size, biocompatibility, and long shelf life.

Some of our designs use soft and flexible polymer “cantilevers” with attached microneedle systems that pop out from the capsule with enough force to release a drug, but without harming the intestinal tissue. While hollow microneedles can directly inject drugs into the intestinal lining, we’ve also demonstrated prototypes that use the microneedles for anchoring drug payloads, allowing the capsule to release a larger dose of medication that dissolves at an exact location over time.

In other experimental designs, we had the microneedles themselves dissolve after injecting a drug. In still others, we used microscale 3D printing to tailor the structure of the microneedles and control how quickly a drug is released—providing either a slow and sustained dose or a fast delivery. With this 3D printing, we created rigid microneedles that penetrate the mucosal lining and gradually diffuse the drug into the tissue, and soft microneedles that compress when the cantilever pushes them against the tissue, forcing the drug out all at once.

Tissue Biopsy via Capsule

Tissue sampling remains the gold standard diagnostic tool in gastroenterology, offering insights far beyond what doctors can glean from visual inspection or blood tests. Capsules hold unique promise here: They can travel the full length of the GI tract, potentially enabling more frequent and affordable biopsies than traditional procedures. But the engineering hurdles are substantial. To collect a sample, a device must generate significant mechanical force to cut through the tough, elastic muscle of the intestines—while staying small enough to swallow.

Different strategies have been explored to solve this problem. Torsion springs can store large amounts of energy but are difficult to fit inside a tiny capsule. Electrically driven mechanisms may demand more power than current capsule batteries can provide. Magnetic actuation is another option, but it requires bulky external equipment and precise tracking of the capsule inside the body.

Our group has developed a low-power biopsy system that builds on the torsion-spring approach. We compress a spring and use adhesive to “latch” it closed within the capsule, then attach a microheater to the latch. When we wirelessly send current to the device, the microheater melts the adhesive on the latch, triggering the spring. We’ve experimented with tissue-collection tools, integrating a bladed scraper or a biopsy punch (a cylindrical cutting tool) with our spring-activated mechanisms; either of those tools can cut and collect tissue from the intestinal lining. With advanced 3D printing methods like direct laser writing, we can put fine, microscale edges on these miniature cutting tools that make it easier for them to penetrate the intestinal lining.

Storing and protecting the sample until the capsule naturally passes through the body is a major challenge, requiring both preservation of the sample and resealing the capsule to prevent contamination. In one of our designs, residual tension in the spring keeps the bladed scraper rotating, pulling the sample into the capsule and effectively closing a hatch that seals it inside.

The Road to Clinical Use for Ingestibles

Looking ahead, we expect to see the first clinical applications emerge in early-stage screening. Capsules that can detect electrochemical, bioimpedance, or visual signals could help doctors make sense of symptoms like vague abdominal pain by revealing inflammation, gut permeability, tumors, or bacterial overgrowth. They could also be adapted to screen for GI cancers. This need is pressing: The American Cancer Society reports that as of 2021, 41 percent of eligible U.S. adults were not up to date on colorectal cancer screening. What’s more, effective screening tools don’t yet exist for some diseases, such as small bowel adenocarcinoma. Capsule technology could make screening less invasive and more accessible.

Of course, ingestible capsules carry risks. The standard hazards of endoscopy still apply, such as the possibility of bleeding and perforation, and capsules introduce new complications. For example, if a capsule gets stuck in its passage through the GI tract, it could cause bowel obstruction and require endoscopic retrieval or even surgery. And concerns that are specific to ingestibles, including the biocompatibility of materials, reliable encapsulation of electronics, and safe battery operation, all demand rigorous testing before clinical use.

A microbe-powered biobattery designed for ingestible devices dissolves in water within an hour. Seokheun Choi/Binghamton University

Powering these capsules is a key challenge that must be solved on the path to the clinic. Most capsule endoscopes today rely on coin-cell batteries, typically silver oxide, which offer a safe and energy-dense source but often occupy 30 to 50 percent of the capsule’s volume. So researchers have investigated alternatives, from wireless power transfer to energy-harvesting systems. At the State University of New York at Binghamton, one team is exploring microbial fuel cells that generate electricity from probiotic bacteria interacting with nutrients in the gut. At MIT, researchers used the gastric fluids of a pig’s stomach to power a simple battery. In our own lab, we are exploring piezoelectric and electrochemical approaches to harvesting energy throughout the GI tract.

The next steps for our team are pragmatic ones: working with gastroenterologists and animal-science experts to put capsule prototypes through rigorous in vivo studies, then refining them for real-world use. That means shrinking the electronics, cutting power consumption, and integrating multiple functions into a single multimodal device that can sense, sample, and deliver treatments in one pass. Ultimately, any candidate capsule will require regulatory approval for clinical use, which in turn demands rigorous proof of safety and clinical effectiveness for a specific medical application.

The broader vision is transformative. Swallowable capsules could bring diagnostics and treatment out of the hospital and into patients’ homes. Whereas procedures with endoscopes require anesthesia, patients could take ingestible electronics easily and routinely. Consider, for example, patients with inflammatory bowel disease who live with an elevated risk of cancer; a smart capsule could perform yearly cancer checks, while also delivering medication directly wherever necessary.

Over time, we expect these systems to evolve into semiautonomous tools: identifying lesions, performing targeted biopsies, and perhaps even analyzing samples and applying treatment in place. Achieving that vision will require advances at the very edge of microelectronics, materials science, and biomedical engineering, bringing together capabilities that once seemed impossible to combine in something the size of a pill. These devices hint at a future in which the boundary between biology and technology dissolves, and where miniature machines travel inside the body to heal us from within.